News

ABBV's successful transition beyond Humira and growth from newer medicines give it an edge over MRK in this oncology-immunology showdown.

With a short percentage of shares outstanding of 1.10%, Eli Lilly and Company (NYSE:LLY) is among the 7 Best Longevity and Anti-Aging Stocks to Buy. On June 16, Austin-based neuroscience company 4E Therapeutics announced that it had been acquired by Eli Lilly and Company (NYSE:LLY). 4E Therapeutics is developing a pipeline of orally available MNK inhibitors designed […]

AbbVie will acquire the clinical-stage biotech’s pipeline of candidates for inflammatory and immunological diseases.

Houman Ashrafian is leaving Sanofi to pursue a new opportunity. Elsewhere, one of Merck’s prized immune drugs succeeded in a pivotal study and a psychedelics biotech’s shares surged.

Doctors are looking for better options given the growing awareness of the serious health risks tied to childhood obesity.

SK Hynix has surpassed Samsung Electronics in market cap for the first time since 2000, now worth more than Bitcoin at $1.35 trillion.

The Health Care Select Sector SPDR ETF (NYSEARCA:XLV) is having a frustrating year. The fund sits at $149, down about 3% year-to-date while the broader market grinds higher. The good news for XLV holders: the fund has clawed back roughly 14% over the past year, and the 2026 setup looks meaningfully different from the policy ... The 2 Factors That Will Decide Whether XLV Finally Catches the S&P 500 in 2026

If you are wondering whether Eli Lilly stock is still worth considering at its current level, the key question is how its price lines up with the underlying value of the business. The share price most recently closed at US$1,098.57, with returns of 5.5% over the past month and 45.1% over the past year, while also showing a decline of 3.0% over the last week and a modest 1.7% gain year to date. Recent coverage of Eli Lilly has focused on its position as a major pharmaceutical company and the...

Pfizer is out of favor right now, and for good reason, but dividend investors may want to take the risk just the same.

Novo Nordisk has been telling investors that volume will eventually offset price cuts, and early results suggest investors should listen.

Eli Lilly's spate of acquisitions is building out multiple areas of its pipeline at once.

These three penny stocks under $5 generate real revenue and have catalysts that analysts believe could drive significant upside

With GLP-1 usage continuing to rise, a group of unlikely beneficiaries is emerging; stocks in the broader health care sector and even in retail could stand out.

Despite several setbacks over the past year, the drugmaker marches on.

These companies don't typically compete directly with one another, but that might change soon.

On June 18, Cathie Wood’s ARK Invest showed off a notable rotation following a superb run in two of the most popular high-growth stocks. Investors had been rewarding Robinhood (HOOD) for its cost-cutting plan and Roku (ROKU) for its takeover-driven rally, but ARK moved in the opposite direction. ...

Eli Lilly (NYSE:LLY) just reported a quarter that should have sent bulls into a frenzy. Revenue grew 55.5% year over year to $19.80 billion, Mounjaro alone delivered $8.66 billion, and management raised full-year guidance to $82 to $85 billion. Yet shares are up just 2.57% year to date at $1,098.57. That disconnect is the entire ... Prediction: Eli Lilly Will Trade at $1,200 on This Date

Cathie Wood Snaps Up $35 Million in Snowflake, Slashes Roku Stake

ARK shifts exposure toward growth and cloud

The foundation behind Novo Nordisk is funding a new effort to turn scientific discoveries into treatments.

By incorporating nonclinical testing services, the partnership seeks to standardise testing protocols across organisations.

RLTs were a hot topic at ASCO 2026, but experts note that certain limitations must be addressed to facilitate their widespread use in cancer care.

AI's next winners in healthcare could be companies like Eli Lilly and Twist Bioscience.

Ricks has led a $50 billion manufacturing Marshall Plan in pharma to safeguard Lilly’s lead in obesity and diabetes treatments.

Eli Lilly (LLY) closed at $1 in the latest trading session, marking a -1.19% move from the prior day.

Eli Lilly and Company (NYSE:LLY) is one of the best growth stocks to buy, according to billionaire Ray Dalio’s Bridgewater Associates. On June 10, the US Food and Drug Administration approved a new dosing regimen for Eli Lilly and Company (NYSE:LLY) in the treatment of patients with moderate to severe atopic dermatitis. The new dosing […]

Eli Lilly is no stranger to the ranks of strong leaders. From the end of 2019 through July 2024, Eli Lilly gained more than 600% with a compound annual growth rate over 55%. Eli Lilly started as a half position but on the follow-up strength the next day, we brought it to a full position (4).

Eli Lilly (LLY) continues to attract attention as investors reassess the stock after recent trading, with shares last closing at US$1,112. With no single headline event, the focus shifts toward fundamentals and recent return patterns. See our latest analysis for Eli Lilly. For context, Eli Lilly’s recent pullback of around 0.9% on the day and 2.1% over the past week comes after a strong 12.5% 1 month share price return and a 42.7% 1 year total shareholder return. This suggests longer term...

FDA accepts RHHBY filing for Lunsumio VELO plus Polivy in relapsed or refractory LBCL as a potential chemotherapy-free treatment option.

After a few days of purging, the Ark Invest growth investor is buying stocks again.